Synlogic, Inc. (NASDAQ:SYBX) Short Interest Update

Synlogic, Inc. (NASDAQ:SYBX) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 61,000 shares, a drop of 30.9% from the December 15th total of 88,300 shares. Based on an average daily volume of 33,100 shares, the short-interest ratio is presently 1.8 days. Approximately 0.9% of the shares of the company are short sold.

Synlogic Stock Down 1.4 %

Shares of NASDAQ:SYBX traded down $0.02 during trading on Friday, reaching $1.43. The stock had a trading volume of 1,939 shares, compared to its average volume of 20,383. The stock has a fifty day simple moving average of $1.42 and a two-hundred day simple moving average of $1.47. Synlogic has a 52 week low of $1.22 and a 52 week high of $3.73. The firm has a market capitalization of $16.73 million, a price-to-earnings ratio of -0.34 and a beta of 0.80.

Synlogic (NASDAQ:SYBX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.17. On average, analysts forecast that Synlogic will post -2.71 EPS for the current year.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.